NCT06931769View on ClinicalTrials.gov

TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer

Not yet recruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

July 1, 2029

Study Completion Date

July 1, 2030

Conditions

Breast Cancer

Trial Locations (1)

Unknown

The Netherlands Cancer Institute, Amsterdam

All Listed Sponsors

collaborator

Dutch Cancer Society

OTHER

lead

The Netherlands Cancer Institute

OTHER